Clinical Trial Update: Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic Stroke [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update evaluating Dl-3-n-butylphthalide and Cerebrolysin for acute ischemic stroke; study completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cerebral Stroke

Drugs mentioned

• Cerebrolysin
• DL-3-n-butylphthalide (DL-3-n-butylphthalide)

Snippet

Sponsor: Shanghai 6th People's Hospital | Conditions: Acute Cerebral Stroke Within 12 Hours for the First Time | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2016-05-18